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INTRODUCTION 74
Metastasis accounts for the majority of breast cancer-related mortalities and approximately 75 40,000 women were expected to die from the disease in 2017 in the US alone (Ghoncheh et 76 al., 2016) . The incidence of brain metastasis in breast cancer patients is estimated at ~30% 77 and is rising, despite more effective systemic therapies (Tabouret et al., 2012) . Therapeutic 78 options consist primarily of surgery, whole brain radiation therapy, stereotactic radiosurgery 79 and chemotherapy but these approaches, while extending life, are rarely curative (Eichler et 80 al., 2011) . While surgical resection improves the overall median survival in the range of 10-81 16 months, surgery is often not feasible for patients with multiple or large brain metastases 82 and progressive extra-cranial disease. Cognitive impairment due to damage to the 83 surrounding normal tissue also limits the dose and therapeutic efficacy of radiation therapy 84 2008; Zhang et al., 2015) . A schematic of the procedure to develop a more robust model of 144 spontaneous brain metastasis is presented in Supplementary Material Fig. S1A . Briefly, 145 parental 4T1 cells were tagged with a mCherry fluorescent marker gene for visualising brain 146 lesions at endpoint and quantitating metastatic burden by genomic qPCR (Martin et al., 2017) . 147
The cells were subjected to four rounds of in vivo enrichment by inoculation of cells in the 148 mammary gland of BALB/C mice, followed by explant cultures of excised brain lesions, 149 fluorescence-activated cell sorting (FACS) and in vitro expansion of mCherry +ve cells to 150 generate the 4T1Br4 line. At this stage the incidence of spontaneous brain metastasis reached 151 20% in mice bearing bulk 4T1Br4 tumours compared to approximately 7% in mice bearing 152 parental 4T1 tumours. Clonal variants were then isolated from the bulk population of 4T1Br4 153 cells by FACS and individually tested in vivo using a low cell number (2 × 10 4 /mouse) to 154 avoid rapid metastatic progression to other organs and/or excessive tumour size requiring 155 early termination of the experiment (Bailey-Downs et al., 2014). Under these conditions, we 156 found extensive variability in the incidence of brain metastasis between clones ranging from 157 0% to 80% (despite similar primary tumour growth rate), indicating that some heterogeneity 158 remains even after serial in vivo selection (Supplementary material Fig. S1B ). Clone 6 (67% 159 incidence) was selected for subsequent experiments and is referred to as 4T1Br4 for brevity. 160
161
The growth rate of 4T1 and 4T1Br4 orthotopic tumours did not differ significantly, indicating 162 that increased brain metastasis in the 4T1Br4 model is not due to faster tumour formation in 163 vivo (Fig. 1A) . In the next series of experiments, tumours were surgically resected when they 164 reached ~0.4 -0.5 g to better reflect the clinical situation and to allow more time for late 165 brain metastases to develop while avoiding growth of primary tumours to unethical size (Fig. 166 1B). In this setting, 4T1Br4 tumours were metastatic to multiple organs, but were selectively 167 more metastatic to brain compared to parental 4T1 tumours (Fig. 1C-E) . 168
Ex-vivo fluorescence imaging of organs from 4T1Br4-bearing mice revealed the presence of 170 multiple lesions in bone and soft tissues including lung and brain. In contrast to the lungs in 171 which multiple lesions were evident, mice typically developed a single brain macrometastasis, 172 most commonly observed in the cerebral cortex ( Fig. 1F ) but also detected occasionally in the 173 cerebellum and leptomeninges (not shown). Brain metastases were highly vascularised ( Fig.  174 1G), proliferative as evidenced by Ki67 IHC staining (Fig. 1H ), expressed cytokeratins (Fig. 175 1I) and were always surrounded by glial fibrillary acidic protein (GFAP +ve ) activated 176 astrocytes ( Fig. 1J ), consistent with a reactive glia (Fitzgerald et al., 2008) . 177
178
The triple negative status of 4T1Br4 primary tumours was confirmed by IHC staining of ER, 179 PR and HER2. As expected, 4T1Br4 tumours showed no evidence of nuclear ER and PR 180 expression and lacked cell surface expression of HER2 ( Fig. 1K , top panels). Discordance 181 in receptor status between primary tumours and brain metastases has been reported in some 182 patients (Duchnowska et al., 2012) . This phenotypic receptor conversion could potentially 183 lead to inappropriate treatment and lack of response to therapy in patients with advanced 184 disease. Hence, we further evaluated ER, PR and HER2 expression in brain metastases. Only 185 weak cytoplasmic (but not nuclear) staining for ER and PR was observed occasionally in 186 some lesions and no HER2 expression was detected indicating that 4T1Br4 brain metastases 187 maintain their triple negative status ( Fig. 1K , middle panels). 188 189 4T1Br4 cells demonstrate enhanced adhesive, migratory and invasive abilities in vitro 190 that are likely to contribute to brain metastasis in vivo. 191
Surrogate in vitro assays were used to gain further insights into the potential functional 192 attributes that contribute to 4T1Br4 preferential metastasis to the brain. Parental 4T1 and 193 4T1Br4 cell showed no significant differences in proliferative rate ( Fig. 2A ) or in their ability 194 to form colonies at low density (Fig. 2B ). In contrast, 4T1Br4 cells were more migratory than 195 4T1 cells in serum chemotaxis assays ( Fig. 2C ). Importantly, 4T1Br4 cells were significantly 196 more adherent to ( Fig. 2D ) and migrated more efficiently than parental 4T1 cells through a 197 monolayer of brain microvascular endothelial cells ( Fig. 2E) . 198 199 For invasion assays, serum-free brain conditioned medium (BCM) was prepared from 200 primary neonatal whole brain explant cultures and used as a chemoattractant. 4T1Br4 were 201 significantly more invasive than 4T1 cells in response to 50% BCM (Fig. 2F ). In contrast, 202 BCM was insufficient alone to promote 4T1Br4 or 4T1 cell proliferation ( Fig. 2G ). Whilst 203 BCM enhanced proliferation in combination with low serum concentrations (1% v/v), it did 204 so to the same extent in 4T1 and 4T1Br4 cells ( Fig. 2G ) indicating that proliferation in 205 response to brain-derived growth factors is unlikely to be a major factor contributing to the 206 brain selectivity of 4T1Br4 tumours in vivo. Similarly, BCM alone did not promote colony 207 formation, nor did it enhance colony formation under low serum conditions in either 4T1 or 208 4T1Br4 cells ( Fig. 2H ). Collectively, these results indicate that 4T1Br4 cells have acquired 209 several functional properties likely to contribute to their greater brain-metastatic abilities, 210 most notably increased endothelial adhesion, trans-endothelial migration and invasive 211 response to brain-derived soluble factors. 212 213
Evaluation of HDAC inhibitor efficacy in the 4T1Br4 model 214
There is increasing interest in the use of HDACi for cancer therapy (Li and Seto, 2016). 215
HDACs regulate multiple processes essential for cancer progression including cell cycle, 216 differentiation, cell motility, autophagy, apoptosis and angiogenesis, by de-acetylating 217 histones and non-histone proteins and altering gene transcription. Changes in their expression 218 and/or activity are common in tumours (Nakagawa et al., 2007; Weichert, 2009 1179.4b inhibited colony formation by ~50% and 100%, respectively, at the same 232 concentration (Fig. 3B ). The effect of SB939 was evident from 500 nM whereas 1179.4b 233 partially inhibited colony formation at concentration as low as 31.25 nM (~30%) and 234 completely blocked colony formation at 250 nM or above (Fig. 3C ). The IC 50 values of 235 these compounds were determined using a 3-day proliferation assay. SB939 and 1179.4b 236 showed greater inhibitory potency than SAHA against 4T1Br4 ( Fig. 3D ) and MDA-MB-237 231Br ( Fig. 3E ). IC 50 values for SAHA were estimated at 1.3 µM and 1.7 µM in 4T1Br4 and 238 MDA-MB-231Br cells respectively ( Fig. 3F ), in good agreement with IC 50 values reported in 239 other tumour models (Atadja, 2009). In contrast, IC 50 for SB939 were 527 nM and 364 nM 240 and for 1179.4b, 71 nM and 50 nM in 4T1Br4 and MDA-MB-231Br respectively. Taken 241 together, these results indicate that SB939 and 1179.4b are significantly more potent than 242 SAHA in inhibiting brain-metastatic breast tumour cells in vitro. Neither SB939 nor 1179.4b has been evaluated in breast cancer brain metastasis models. In 273 preliminary experiments we confirmed that SB939 or 1179.4b (both at 10, 20 or 40 mg/kg) 274 administered intraperitoneally once daily for 8 days in BALB/C mice were well tolerated, 275 with no significant decrease in body weight or changes in overall appearance or behaviour 276 (data not shown). However, 1179.4b (40 mg/kg) had poor solubility in 30% polyethylene 277 glycol, and therefore a dose of 20 mg/kg was chosen for subsequent in vivo experiments. For 278 SB939, the dose was increased to 50 mg/kg since it retained good solubility at this 279 concentration and was well tolerated at the highest dose tested (40 mg/kg). To investigate 280 the effect of SB939 and 1179.4b on tumour growth in vivo, 4T1Br4 cells were injected into 281 the mammary fat pad and drug treatment initiated on day 9, when primary tumours were 282 palpable. SB939 (50 mg/kg) and 1179.4b (20 mg/kg) were injected intraperitoneally once 283 daily until completion of the experiment on day 28. Both SB939 and 1179.4b significantly 284 reduced 4T1Br4 primary tumour growth ( Fig. 4A ) and tumour weight at endpoint ( Fig. 4B ) 285 compared to control mice. Primary tumours were analysed for changes in histone H3 286 acetylation by immunoblotting ( Fig. 4C ). As expected, SB939-or 1179.4b-treated mice 287 showed a strong increase in acetylation of histone H3 in primary tumours compared to 288 tumours from control mice, confirming that both SB939 and 1179.4b effectively blocked 289 HDAC activity in vivo and caused reduced primary tumour growth. 290
291
While the primary objective of this experiment was to evaluate the impact of SB939 and 292 1179.4b on primary tumour growth, spines were also collected and relative tumour burden 293 was measured by genomic qPCR detection of the mCherry marker gene. Interestingly, 294 metastatic burden in spines was significantly reduced by SB939 or 1179.4b ( Fig. 4D ). Brain 295 metastasis was not evaluated in this experiment since fewer mice/group (8-9) were used, 296 tumours were not resected, and the experiment had to be terminated earlier (day 28) due to 297 the large primary tumour size/weight in the control group and early signs of lymphopenia 298 occurring in mice treated for extended time (19 days) with 1179.4b. 299
300
To investigate the effects of SB939 and 1179.4b specifically on spontaneous brain metastasis, 301 4T1Br4 cells were injected into the mammary fat pad and the tumours resected when they 302 reached approximately 0.5 g. Treatment with SB939 (50 mg/kg) or 1179.4b (10 mg/kg) was 303 initiated two days after tumour resection. Tumour weights at resection were not significantly 304 different between groups (Fig. 4E ). Brains were examined by fluorescence imaging at 305 endpoint (day 33) and the incidence of mice with detectable mCherry +ve lesions was scored 306 ( Fig. 4F ). Under those conditions, SB939 and 1179.4b reduced the incidence of mice with 307 detectable brain lesions from 45% (5/11) in the control group to 18% (2/11) and 8% (1/12) in 308 SB939 and 1179.4b-treated mice, respectively. 309
310
The results above indicate that SB939 and 1179.4b inhibit spontaneous brain metastasis but 311 do not address whether they do so by preventing the establishment of brain metastases or by 312 inhibiting directly their outgrowth in the brain. We addressed this using an experimental 313 metastasis assay in which tumour cells are inoculated directly into the vasculature, with 314 treatment commencing 2 days after cell inoculation and continuing until day 12. The presence 315 of brain metastases at endpoint was confirmed by scoring the extent of cytokeratin +ve tumour 316 cells by IHC in whole brain sections. Experimental brain metastasis was inhibited partially 317 by 1179.4b, but not by SB939 in this protocol (Fig. 5A ). The presence of viable circulating 318 tumour cells (CTC) in blood collected from each experimental group was evaluated in a 319 colony formation assay. Consistent with the inhibition of metastasis to brain and other soft 320 tissues observed in 1179.4b-treated animals, the number of colonies formed was dramatically 321 reduced compared to control, whereas SB939 had no significant effect ( Fig. 5B ). These 322 results indicate that 1179.4b may inhibit brain metastasis primarily by targeting CTCs, 323 thereby preventing their homing and outgrowth in brain (and other organs) rather than 324 inhibiting established metastases directly. Consistent with this possibility, metastases in other 325 soft tissue were also scored semi-quantitatively by visual examination at necropsy and 326 showed a reduction in the incidence of ovary, kidney and adrenal gland metastases in 327 1179.4b-but not SB939-treated mice ( Fig. 5C ). 328 329 SB939 and 1179.4b sensitise brain-metastatic cells to radiation 330 Whole brain radiation therapy (WBRT) remains the cornerstone of treatment for brain 331 metastasis and its efficacy is increasingly being explored in combination with other 332 therapeutic modalities (Tallet et al., 2017) . Several HDACi, including SAHA, have been reported to sensitise tumour cells to radiation (Baschnagel et al., 2009; Chiu et al., 2013), a 334 strategy that has the potential to increase the efficacy of radiation therapy while minimising 335 its side effects. Therefore, the radiosensitising properties of SB939 and 1179.4b were 336 evaluated first in 4T1Br4 cells using in vitro colony forming assays. Each HDACi was used 337 at their IC 50 concentration either alone or in combination with increasing radiation doses. 338
Both SB939 and 1179.4b significantly enhanced radiation-induced cell death, resulting in 339 fewer colonies compared to radiation alone ( Fig. 5D ). Dose enhancement factor (DEF) at 50% 340 cell survival was 1.45 for both SB939 and 1179.4b. 341
342
Since MDA-MB-231Br cells are highly motile and tend to scatter in colony assays, we used 343 an alternative method to quantitate the radio-sensitising effects of SB939 and 1179.4b by 344
measuring the induction of γ -H2AX nuclear foci. We interrogated sorted tumour cells from the 4T1Br4 primary tumours versus those of highly 362 (non-brain) metastatic 4T1 variants (4T1.2ncA5, 4T1.13ch5, 4T1BM2ch11, 4T1ch9) and an 363 isogenic non-metastatic line (67NRch1), to identify genes associated with brain-specific 364 metastasis. While our model clearly recapitulates the clinical brain-metastatic phenotype in 365 similarly reflective of the human disease and could therefore allow identification of potential 367 therapeutic targets. By utilising the Affymetrix Mouse Exon 1.0 ST Array with updated 368 probeset definitions that retained only those probes mapped unambiguously to the latest 369 genome build (Dai et al., 2005) , we measured the expression of 32,722 unique ENSEMBL 370 Gene IDs. To compare our data with human clinical cohorts and gene signatures, these IDs 371 were converted to the HGNC Symbols of their corresponding human homologs (as per Table  372 S1) for all subsequent analyses. 373
374
We reasoned that by identifying differentially expressed genes among brain-metastatic 375 tumours of the 4T1Br4 model in combination with those of the Bos GSE12276 cohort, to the 376 exclusion of genes associated with non-brain metastasis, we would derive a more brain-377 specific and clinically relevant gene signature with which to elucidate the underlying biology 378 driving brain metastasis in breast cancer patients. To identify genes associated with 379 promotion of brain-specific metastasis, we used "limma" (Ritchie et al., 2015) to measure 380 differential expression (fold change ≥ 1.5, p ≤ 0.05) shared by tumour transcriptomes of 381 4T1Br4 brain metastatic versus highly metastatic (Table S2 ), 4T1Br4 brain-versus non-382 metastatic (Table S3 ) and Bos (GSE12276) brain-versus non-metastatic tumours (Table S4) , 383 that was not shared in 4T1 highly-versus non-metastatic tumours (Table S5 ). The resulting 384 gene lists (Table S6) (Table S7) (Table S9 -13), comprised of brain-and non-brain 393 metastatic phenotypes. Specifically, we compared enrichment in brain-metastatic samples for 394 our BrCa BSM gene set versus recently published gene sets associated with brain-metastasis 395 derived from human breast cancer expression profiles of brain-metastatic primary tumours 396 and cell lines ((Bos et al., 2009) Tables S4 and S7 therein). In addition, we created custom 397 gene sets derived from differentially expressed genes of brain-versus non-brain metastatic 398 tumours (Table S2 -4, S14-18), using GSEA as a surrogate measure of the similarity and hence, the clinical relevance of the 4T1Br4 model and the BrCa BSM gene set. We found that 400 4T1Br4 brain-metastatic tumours were significantly positively enriched for the brain 401 metastasis-associated gene sets from human tumours ("Bos BrMS UP") and cell lines ("Bos 402 CN34-231 BrM UP") ( Fig. 6B-D) . Importantly, the 4T1Br4 brain-metastatic tumours were 403 also significantly enriched for gene sets derived from up-regulated genes of all brain-404 metastatic samples and those of the TNBC subtype within GSE12276 (Table S19) . 405 406 Next, we compared enrichment for the BrCa BSM gene set versus the other brain metastasis 407 signatures in GSE12276 and sought confirmation that the brain-metastatic tumours of this 408 human clinical cohort were enriched for gene sets derived from 4T1Br4 differential 409 expression (Table S17 ). Significantly, enrichment for the BrCa BSM gene set in the 410 GSE12276 brain-metastatic tumours was greater and more significant than for "Bos BrMS 411 UP" and "Bos CN34-231 BrM UP" gene sets (NES = 3.04, FDR < 0.001, versus NES = 1.77, 412 FDR = 0.002 and NES = 1.57, FDR = 0.010, respectively) and GSE12276 brain-metastatic 413 tumours were indeed enriched for differentially expressed genes of 4T1Br4 versus non-414 metastatic tumours ( Fig. S3 , Table S20 ), consistent with the clinical relevance of 4T1Br4. To 415 determine whether the results detailed herein were unique to 4T1Br4 and GSE12276 or may 416 have more universal applicability, we utilised the GSE46928 cohort comprised of brain-and 417 highly-metastatic tumours to test enrichment for corresponding gene sets (Table S18 ). Indeed, 418 brain-metastatic tumours of GSE46928 were significantly enriched for several 4T1Br4 and 419 GSE12276 differential expression gene sets and once again, BrCa BSM exhibited the greatest 420 enrichment ( Fig. S4 , Table S21 ). Collectively, these GSEA data (Table S22) To gain insights into the underlying biology driving breast cancer brain-specific metastasis, 426 we used two approaches. First, we uploaded the BrCa BSM gene set with associated fold-427 changes and p-values from 4T1Br4 versus non-metastatic tumours (Table S23) Table S24 ). Similarly, enrichment results for Process Networks (Table S25) , Diseases 434 (Table S26 ) and GO Processes (Table S27) were also dominated by pathways and processes 435 involved in immunity. Clearly, tumour-intrinsic immune regulation is of paramount 436 importance in breast cancer brain-specific metastasis. 437 438 Second, we sought to identify curated Molecular Signature Database (MSigDB) gene sets 439 (Canonical pathways, BioCarta, KEGG and Reactome; v6.1) associated with breast cancer 440 brain-specific metastasis (BrCa BSM pathways), in an approach analogous to derivation of 441 the BrCa BSM gene set. Specifically, GSEA was completed to detect positive enrichment of 442 curated gene sets shared among the brain-metastatic samples of expression datasets for the 443 4T1Br4 model (Table S9 -10) and GSE12276 (Table S11 ) that were not enriched in highly 444 metastatic samples of the 4T1 (HighMet versus NonMet) expression dataset (Table S12 ). The 445 curated gene sets so derived define the BrCa BSM pathways (Table 1 ). In support of our 446 functional assays ( Fig. 2D, E) , the most significantly enriched pathway (FDR = 3.11 × 10 -3 ) 447 relates to a critical mechanism that permits tumour cell colonisation of the brain -trans-448 endothelial migration across the BBB (Bos et al., 2009). To prioritise potential therapeutic 449 targets driving brain-specific metastasis, we identified 11 consensus genes contributing to 450 enrichment in this 80-gene pathway across all brain-metastatic 4T1Br4 and GSE12276 451 tumours, two of which met the differential expression threshold (FC ≥ 1.5, pval ≤ 0.05) to 452 qualify as members of the BrCa BSM gene set: FCER1G and PECAM1 (Table S28 ). In 453 support of the MetaCore pathway analysis, immune pathways also featured prominently 454 among the MSigDB curated gene sets enriched in brain-metastatic tumours. Taken together, 455 these analyses strongly implicate tumour-intrinsic immune regulation and underscore the 456 importance of tumour cell interactions with the vasculature in breast cancer brain metastasis. 457 458 DISCUSSION 459
We have described the successful development of a new model of breast cancer brain 460 metastasis that incorporates several elements of clinical relevance including robust 461 spontaneous spread from the mammary gland to the brain in immune competent animals. 462 TNBC is characterised by earlier onset of metastasis compared to other molecular subtypes 463 and high incidence of brain metastasis, often with extensive extracranial involvement as well. 464
While 4T1Br4 and parental 4T1 tumours have a pattern of metastatic spread that is similar to 465 that reported for human TNBC (Liedtke et al., 2008), we found that 4T1Br4 tumours are 466 selectively more metastatic to the brain compared to parental 4T1 tumours. To the best of our 467 knowledge, 4T1Br4 tumours show the highest incidence of spontaneous breast cancer brain 468 metastases among all syngeneic mouse models described so far. While other investigators 469 have reported on the use of brain-tropic 4T1 cell variants with distinct growth and phenotypic exploited by our group previously to derive highly bone-metastatic (but not brain-metastatic) 486 4T1 variants (Kusuma et al., 2012). It is also noteworthy that differences in the anatomical 487 location and number of brain lesions were observed between spontaneous and experimental 488 metastasis assays. While experimental metastasis assays gave rise to multiple metastatic foci 489 scattered through the cerebrum, cerebellum, leptomeninges and olfactory lobes, only one or 490 two brain lesions most commonly formed in the cerebrum in the spontaneous metastasis assay. The latter appear to be more representative of the pattern of brain metastasis observed 492 in the clinic (Delattre et al., 1988 ). These differences can be explained in part by the large 493 number of cells injected directly into the vasculature in experimental metastasis assays, 494 resulting in multiple clones successfully homing to and colonising the brain, including those 495 that may not possess all functional attributes required for spontaneous brain metastasis. In addition, our analyses revealed the importance of tumour-intrinsic immune regulation in 519 brain-specific metastasis, due in no small part to the many differentially expressed genes 520 traditionally viewed as leukocytic markers, FCER1G chief among them. These observations 521 are not without precedent, as several studies have reported similar "inappropriate gene 522 expression" of leukocytic markers in metastatic breast and other cancers (Tarin, 2012) . Hence, 523 tumour-specific FCER1G and PECAM1 may represent bona fide therapeutic targets that 524 warrant further evaluation. 525
526
The high incidence of spontaneous 4T1Br4 brain metastasis makes this model ideally suited 527 for pre-clinical evaluation of new therapeutics. Our in vitro investigation showed that SB939 528 and 1179.4b are significantly more potent than SAHA at inhibiting the proliferation/survival 529 of 4T1Br4 and human MDA-MB-231Br brain-tropic lines, in agreement with the higher 530 Future studies will be required to confirm this possibility. 566
567
In the adjuvant setting, where therapy was initiated after removal of the primary tumour, 568 SB939 and 1179.4b dramatically reduced the number of detectable brain lesions. It was not 569 possible to determine whether spontaneous brain micrometastases were already present prior 570 to the beginning of HDACi treatment due to the limited mCherry fluorescence signal in 571 micro-lesions. Thus, it is unclear whether these HDACi directly inhibited established brain 572 metastases or effectively killed circulating breast cancer cells in the vasculature before they 573 home to and colonise the brain (preventive effect). Structurally, SB939 meets several 574 requirements for BBB penetration including low molecular weight (≤ 500 Da) and oil/water 575 distribution coefficient (LogP ≤ 5) and absence of efflux ratio indicating that it is unlikely to 576 be a P-glycoprotein transporter substrate (Jayaraman et al., 2011). However, the lack of 577 effect of SB939 on experimental brain metastasis indicates that it may not reach sufficient 578 concentrations in the brain (or other visceral metastases) to achieve clinical significance. 579
Whilst 1179.4b partially inhibited experimental brain metastasis, its predicted limited 580 permeability across the BBB suggests that its effect is likely to be primarily preventive. In 581 support of this, we found that the number of viable CTCs in blood as well as ovary, kidney 582 and adrenal metastases were reduced in 1179.4b-treated mice. However, given the high 583 potency of 1179.4b compared to SAHA or SB939, we cannot completely rule out that low 584 levels of this inhibitor may be sufficient to exert a direct effect on brain metastases in which 585 the BBB is disrupted, as seen in some TNBC patients (Yonemori et al., 2010) . The 4T1Br4 model of brain-metastatic breast cancer closely recapitulates the human disease 600 at phenotypic, functional and transcriptomic levels. Therefore, we believe that our model is 601 clinically relevant and an ideal system in which to identify potential therapeutic targets and 602 evaluate the efficacy of pharmacological and/or genetic interventions. Notably, expression 603 profiling and related analyses demonstrated the critical role of tumour-intrinsic immune 604 regulation in brain-specific metastasis, underscoring the importance of using immune-605 competent models as tools for discovery and for translational studies that may incorporate 606 immunotherapeutic strategies. These data also implicated tumour cell surface interactions 607 with the vasculature in successful colonisation of the brain, in support of previous studies and 608 functional assays herein. Significantly, curated gene set enrichment analysis identified several 609 potential therapeutic targets for future evaluation, with FCER1G and PECAM1 emerging as 610 promising candidates. Evaluation of HDACi efficacy in this model demonstrated partial 611 efficacy of SB939 and the more potent 1179.4b against mammary tumours and metastases, 612
including to the brain. However, these compounds are unlikely to be sufficient alone to fully 613 control advanced metastatic disease and will require combination therapies to achieve 614 clinically relevant disease control, in particular brain metastasis. Several clinical trials 615 combining HDAC inhibitors and radiation therapy are now underway or in recruitment phase, 616 some aimed specifically at treating brain metastases from solid tumours (Groselj et al., 2013). 617
Our preliminary assessment of the radio-sensitising properties of SB939 and 1179.4b in vitro 618 warrants further investigation of their therapeutic potential in combination with WBRT 619 against brain metastasis. 620
MATERIALS AND METHODS 621
Cell culture and reagents 622
The 4T1 and 67NR mouse mammary carcinoma cell lines were obtained from Dr. Tissues were dissected, fixed in 10% buffered formalin and processed for paraffin embedding. 675
Serial sections from primary tumour (4 µm) or brain (6 µm) were stained with haematoxylin 676 and eosin (H&E) for morphology or subjected to standard IHC staining (Martin et al., 2017). 677
Briefly, paraffin sections were de-waxed in xylene and rehydrated in graded ethanol solutions 678 prior to heat induced epitope retrieval in 10mM citrate buffer (pH 6.0). The following 679 primary antibodies were used: ERα (DAKO, cat. #M7047), PR (Santa Cruz Biotech, cat. # 680 SC-538), HER2 (Calbiochem, cat. #OP15L), pan cytokeratin (SIGMA, cat #C1801), Ki-67 681 (Abcam, cat. #Ab15580) and anti-GFAP (DAKO, cat #Z0334). Specific binding was detected 682 using appropriate biotin-conjugated secondary antibodies and ABC reagents (Vectastain kit 683 #PK6100, Vector Laboratories). Staining was visualised with 3,3'-diaminobenzidine (DAB) 684 and a haematoxylin counterstain. 685
SDS-PAGE and acetylated histone H3 immunoblotting 687
Whole cell lysates from control and HDACi-treated sub-confluent cells cultures or crushed 688 frozen tumours were prepared in ice-cold RIPA buffer [10 mM Tris-HCl (pH 7.4), 5 mM 689
supplemented with protease inhibitor cocktail (ROCHE, cat. #04693132001). Lysates were 691 sonicated four times for 30 sec, cleared by centrifugation at 13,000 × g for 15 min at 4°C and 692 the supernatants stored at -20°C. 693
Western blotting was performed using standard methodology as described previously 694 (Denoyer et al., 2014) . Briefly, 40 µg of proteins were separated on a 15% SDS-PAGE gel 695 and transferred to a PVDF membrane. The membrane was blocked with 10% (w/v) non-fat 696 dried milk in PBS containing 0.05% Tween-20 for 1 hour at room temperature and incubated 697 with anti-acetylated histone H3 antibody (Millipore, cat. #06-599, 1:10,000 dilution) 698 overnight at 4°C. After 3 washes with wash buffer (0.025% Tween-20 and 0.1% BSA in PBS) 699 for 10 min, the membrane was incubated for 1 hour with an appropriate horseradish 700 peroxidase-conjugated secondary antibody in wash buffer. Specific protein bands were 701 detected using enhanced ECL reagents and Super RX film or ChemiDoc™ MP System 702 (Biorad). An anti-GAPDH antibody (Abcam, cat. #Ab8245, 1/10000 dilution) was used as 703 loading control. 704 705
Preparation of brain conditioned medium (BCM) 706
Newborn pups from BALB/C mice were rinsed quickly with 70% alcohol and whole brains 707 removed under sterile conditions. Brains were rinsed twice quickly with 20 mL PBS 708 containing 2% penicillin-streptomycin and fluconazole (6 µg/mL), minced with a scalpel 709 blade and cultured in DMEM supplemented with 20% FBS, 1mM sodium pyruvate, 710 fluconazole (6 mg/L) and 2% penicillin-streptomycin at 37℃ with 5% CO 2 . The medium was 711 changed every 2-3 days until subconfluent. Adherent cells were serum-starved overnight in 712 15 mL α -MEM serum free medium (SFM) supplemented with 0.05% bovine serum albumin 713 (BSA), 2 mM L-glutamine, 1 mM sodium pyruvate and 1% penicillin-streptomycin and the 714 medium replaced with 10 mL of fresh SFM. Serum-free BCM was collected after 48 hours, 715 centrifuged at 1200 rpm, at 4℃, for 5 min and stored at -80℃ until used. BCM was stable for 716 at least 3 months at -80℃. 717 718
Colony formation assay
Colony formation assays were done as described previously with minor modifications 720 
Migration and invasion assays 747
Chemotactic migration assays were completed in triplicate Transwell polycarbonate 748 membrane inserts (8 µm pore size) (Corning Inc., Life Sciences, NY, USA) as described 749
previously (Sloan et al., 2006) . Tumour cell migration to the underside of porous membranes 750 was measured after 4 hours of incubation at 37℃. Cells on the underside of membrane were 751 fixed in 10% neutral buffered formalin, permeabilised for 5 min in 0.1% Triton X-100 and stained with 0.5µg/mL 4′,6-diamidino-2-phenylindole (DAPI). For invasion assays, tumour 753 cells (1x 10 5 ) were embedded in 100 µL of a 1:1 mixture of SFM and Matrigel (BD 754 Biosciences, CA, USA) in the upper wells and allowed to invade and migrate towards SFM 755 (control) or 50% BCM. The number of cells on the underside of the porous membrane was 756 scored after 18 hours of incubation at 37℃, as described for migration assays. Following 24 hours incubation at 37°C, cells were irradiated with 1 Gy. One or 24 hours after 804 irradiation, cells were rinsed in PBS and fixed with 4% PFA for 30 minutes, placed in 70% 805 ice-cold ethanol and stored at 4°C. For γ -H2AX staining, cells were washed with PBS for 15 806 min at room temperature and blocked with 8% BSA in PBS containing 0.5% Tween-20 and 807 0.1% Triton X-100 (PBS-TT) for 30 min at RT. Slides were incubated with an anti-γ-H2AX 808 antibody (Abcam, cat. #Ab11174, 1:500 dilution in 1% BSA in PBS-TT) for 2 hours at room 809 temperature under a humidified atmosphere before washing three times with PBS for 5 810 minutes and incubated with a secondary antibody (Alexa fluor 488 conjugated goat anti-811 rabbit IgG, 1:500 dilution in 1% BSA in PBS-TT) for 1 hour at room temperature. Slides 812 were washed three times as above and mounted with a Vectashield mounting medium Derivation of the breast cancer brain-specific metastasis (BrCa BSM) gene set 857
The intersection of differentially expressed gene lists from brain-("BrMet") versus highly-858 ("HighMet") and non-metastatic ("NonMet") tumours was implemented with VennPlex 859 software (Cai et al., 2013) to identify consensus 'driver' genes associated with brain 860 metastasis from the 4T1Br4 and Bos GSE12276 cohorts. Specifically, the genes of interest 861 corresponded to those common to 4T1 brain-metastatic versus highly-metastatic ("BrMet v 862
HighMet", Table S2 ), 4T1 brain-versus non-metastatic ("BrMet v NonMet", Table S3 ), Bos 863 brain-metastatic versus local/non-recurring ("Bos BrMet v NonMet", Table S4 ) and not 864 including 4T1 highly-versus non-metastatic ("HighMet v NonMet", Table S5 ) differentially 865 expressed genes. The intersection of these gene lists (Table S6 ) resulted in 45 distinct regions 866 (Table S7) , with "region_30" corresponding to the BrCa BSM gene set ( Fig. 6A , "*"; Table  867 S8). 868 869
Gene set enrichment analysis and derivation of BrCa BSM pathways & targets 870
Gene set enrichment analysis (GSEA) (Subramanian et al., 2005) was utilised to enable 871 detection of co-ordinated expression across sets of genes in brain-versus non-brain metastatic 872 tumour expression datasets (log2 RMA-normalised expression values, Table S9 -13). 873
Phenotype labels were associated with each sample according to our site-specific metastasis 874 data or from corresponding clinical data available from ArrayExpress. The GSEA desktop 875 application and curated gene sets were downloaded from the Broad Institute GSEA site 876 (http://software.broadinstitute.org/gsea/index.jsp). Analyses were performed with 1,000 gene 877 set permutations using native HGNC gene symbol identifiers. Custom gene sets for brain-878 versus non-brain metastatic samples of the 4T1 and Bos cohorts (Table S16-18) were 879 constructed from corresponding lists of differentially expressed genes (Table S2 -4, S14-15); 880 TNBC samples within GSE12276 were identified as per associated hormone receptor clinical 881 data. The "Bos BrMS UP" and "Bos CN34-231 BrM UP" brain metastasis gene sets were 882 derived from (Bos et al., 2009), Supplementary Tables 4 and 7, respectively. Gene set 883 enrichment reports for 4T1 (Table S19) , GSE12276 (Table S20 ) and GSE46928 (Table S21) expression datasets correspond to positive enrichment of the given gene sets in the brain-885 versus non-brain metastatic samples, ordered by FDR q-val, then normalized enrichment 886 score (NES); GSEA analyses for all cohorts were summarized (Table S22 ). To identify 887 positive enrichment for curated MSigDB gene sets (Canonical pathways, BioCarta, KEGG 888 and Reactome; MSigDB v6.1) associated with breast cancer brain-specific metastasis (BrCa 889 BSM pathways), GSEA was used to identify curated gene sets enriched in the brain-890 metastatic samples of expression datasets for 4T1 BrMet versus HighMet (Table S9 ), 4T1 891 BrMet versus NonMet (Table S10 ) and Bos BrMet versus NonMet (Table S11) that were not 892 enriched in highly metastatic samples of the 4T1 HighMet versus NonMet expression dataset 893 (Table S12 ). The unique curated gene sets commonly enriched in brain-metastatic samples 894 across 4T1 and GSE12276 cohorts correspond to the BrCa BSM pathways (Table 1) . 895
896
GeneGO MetaCore pathway analysis 897
To gain insights into the functional pathways and processes underlying the BrCa BSM gene 898 set, the HGNC Symbols, fold-changes and p-values of the 34 up-regulated genes in 4T1Br4 899 brain-versus non-metastatic tumours (Table S23) 
